Skip to content

Catheter ablation versus video assisted thoracoscopic surgery for the treatment of (longstanding) persistent atrial fibrillation

Catheter ablation versus video assisted thoracoscopic surgery for the treatment of (longstanding) persistent atrial fibrillation - The CAVIAR-trial

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41871
Enrollment
60
Registered
2015-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Minimally invasive surgical ablation through video assisted thoracoscopic surgery
Atrial fibrillation
Catheter ablation
Minimal invasive surgery
Video assisted thoracoscopic surgery

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Patients age is * 18 years - Patients with persistent or longstanding persistent atrial fibrillation. - Patients undergoing a first time invasive treatment procedure for persistent atrial fibrillation - AF must be recorded at least once by ECG, holter, telemetry, loop recorder or internal device. - Patients must give informed consent to participate

Exclusion criteria

Exclusion criteria: - Patients suffering from paroxysmal atrial fibrillation - Patients with any exclusion criteria or contra-indications for electrophysiologic study and ablation in the left atrium, such as pregnancy or presence of a left atrial thrombus - Patients with any contra-indications for VATS such as pleural adhesions, elevated hemidiaphragm or prior lung/cardiac surgery - Active infection or sepsis - Body mass index> 40 - mitral or aortic valve regurgitation above grade 2 - moderate to severe mitral or aortic stenosis

Design outcomes

Primary

MeasureTime frame
-Success after 1 procedure with a follow-up duration of 12 months. Success is defined as: freedom of atrial fibrillation/atrial flutter/atrial tachycardia >30 seconds following the 3 months blanking period in the absence of Class I and III AAD therapy.

Secondary

MeasureTime frame
-The incidence of periprocedural complications. -Clinical success (75% or greater reduction in the number of AF episodes, the duration of AF episodes, or the % time a patient is in AF in the presence or absence of previously ineffective AAD therapy) after the first procedure. -Procedural duration. -Success and clinical success after 2 procedures with a follow-up duration of 12 months. A second procedure will be performed through catheter ablation in both groups. -Quality of life measurements before and 6 months after the first procedure.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)